Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| (4 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| − | *[[Media: | + | *[[Media:2021_07-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|July 27, 2021]] |
| − | *[[Media: | + | *[[Media:2021_04-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|April 27, 2021]] |
| − | *[[Media: | + | *[[Media:2021_03-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|March 23, 2021]] |
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 16:13, 24 August 2021
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease